HRC0202 vs Zevorcabtagene autoleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
HRC0202
Developed by Hrain Biotechnology Co., Ltd.
NCT04003168 · Phase 1 · status unknown
This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The published report covers seven treated patients, fewer than the study's listed enrollment.
Reported efficacy
Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0 (28 days post infusion): In seven patients with relapsed/refractory multiple myeloma previously treated with anti-BCMA CAR-T (four relapsed, three refractory), the best overall response rate was 71.4% (5/7), with stringent complete response or complete response achieved in three patients. Cytokine release syndrome of grades 1-2 occurred in three patients (42.9%) and grade >=3 in two patients (28.6%).
Result source: NCT04003168
Zevorcabtagene autoleucel
Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners
NCT03975907 · Phase 1/2 · status unknown
This study enrolled every patient into a single treatment group, with no comparison arm and no blinding, so there is no control group to judge the response rate against. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The registered phase 1 primary endpoint of this study is dose-limiting toxicity; the response rates shown are the phase 2 portion's primary endpoint (overall response rate).
Reported efficacy
Phase 1, Safety and tolerability: dose limiting toxicity (28days post administration of CAR-T-cells); Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate (3 months post administration of CAR-T-cells): LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). (met)
Result source: NCT03975907
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HRC0202 | Zevorcabtagene autoleucel |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| VGPR or better | —Not reported | —Not reported |
| MRD negativity | —Not reported | —Not reported |
PFS, median
- HRC0202
- —Not reported
- Zevorcabtagene autoleucel
- —Not reported
OS, median
- HRC0202
- —Not reported
- Zevorcabtagene autoleucel
- —Not reported
ORR
- HRC0202
- —Not reported
- Zevorcabtagene autoleucel
- —Not reported
VGPR or better
- HRC0202
- —Not reported
- Zevorcabtagene autoleucel
- —Not reported
MRD negativity
- HRC0202
- —Not reported
- Zevorcabtagene autoleucel
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HRC0202: no structured comparison results are available for Multiple Myeloma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRC0202's landscape · Zevorcabtagene autoleucel's landscape